LULULEMON/UN-FOUNDATION
lululemon and the United Nations Foundation today announced their partnership around an innovative program to address the mental and physical health of UN development and humanitarian workers who serve on the front lines of urgent global challenges, so they can better support communities around the world. lululemon will commit $1 million USD over the next three years to Peace on Purpose, an evidence-based program, which provides access to mindfulness and self-care tools and resources for UN workers to build resilience in the face of adversity and stressful environments – such as responding to humanitarian emergencies, supporting communities facing poverty, and more. Peace on Purpose's mission is to equip aid workers with the tools to care for themselves so they can effectively care for others.
“lululemon and the UN Foundation share a commitment to building community and developing collaborative solutions for some of the world’s most pressing issues,” said Calvin McDonald, CEO of lululemon. “With increasing need for international humanitarian aid and peacekeeping, we want to cultivate the long-lasting benefits of mindfulness tools and sustain support for those whose mission is to serve others.”
“UN workers are on the front lines of global challenges, helping people in their times of greatest need,” said Kathy Calvin, President and CEO of the UN Foundation. “This work can often be stressful, and the UN has made it a priority to address the well-being of its people. Innovative partnerships like Peace on Purpose can support the UN workers who support the world. With lululemon’s support, we will be able to grow the program to help more UN staff care for themselves and for others.”
Peace on Purpose is a result of a three-year pilot led by lululemon’s Here to Be team and the UN Foundation, developed to address a series of issues, such as burnout, compassion fatigue, and stress-related physical, mental, and relational effects reported by UN staff members. Peace on Purpose has worked with UN agencies to build out trainings and workshops for more than 650 staff in US headquarters and seven additional countries – Jordan, Lebanon, Pakistan, South Sudan, Turkey, Turkmenistan and Zimbabwe.
Research that followed select trainings found that over half of the participants experienced a more than 40 percent improvement in overall well-being as seen in key psychological risk factors, such as work-related self-compassion, anxiety and depression, symptoms related to trauma, and feelings of distress.
Humanitarian aid workers report experiencing high rates of burnout, stress, and mental health stigmas in difficult global settings. Peace on Purpose’s curriculum introduces mindfulness tools as well-being resources to support current UN mental health programs. These tools – such as mindful breaths, emotion regulation, and yoga – can be implemented to meet the varying needs of UN staff in the diverse environments in which they operate.
With lululemon’s continued funding commitment and thought partnership, Peace on Purpose will aim to train 3,000 more UN development and humanitarian workers in-person over the next three years, build a hub of digital resources, and develop condensed trainings and curriculum translations to reach an additional 30,000 UN staff.
Peace on Purpose is a key element of lululemon’s commitment to social impact and sustainability. The company’s Impact Agenda is comprised of three elements – Be Human, Be Well and Be Planet – to support and accelerate meaningful positive impact around the world.
To learn more about Peace on Purpose or lululemon’s Global Impact Agenda, including Here to Be, visit https://shop.lululemon.com/story/sustainability .
About lululemon athletica inc.
lululemon athletica inc. (NASDAQ:LULU) is a healthy lifestyle inspired athletic apparel company for yoga, running, training, and most other sweaty pursuits, creating transformational products and experiences which enable people to live a life they love. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback. For more information, visit www.lululemon.com
.
About the United Nations Foundation
The United Nations Foundation acts as a strategic partner to help the United Nations mobilize the ideas, people, and resources it needs to drive global progress and tackle urgent challenges. We focus on issues at the heart of the Sustainable Development Goals, build initiatives across sectors to solve problems at scale, and engage citizens who seek action. Founded in 1998 by entrepreneur and philanthropist Ted Turner, the UN Foundation works with philanthropic, corporate, government, and individual partners. Learn more at www.unfoundation.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom